Healthcare · NYSE/NASDAQ: VRTX
VERTEX PHARMACEUTICALS INC / MA
Biotechnology
Market Cap $114.33B
Verdict: Exceptional
Quality Scores
Multi-Bagger
88/100
Compounder Quality
91/100
Management Credibility
95/100
Governance
94/100
Cash Flow Quality
90/100
AI Summary
Vertex Pharmaceuticals (VRTX) has undergone a spectacular transformation over the last decade, evolving from a cystic fibrosis (CF) specialist into a diversified biotech powerhouse with a dominant market position. The financial trajectory shows revenue growing from roughly $458M in 2016 to over $12B by 2025, representing an elite compounding profile. Despite a significant one-time GAAP loss in 2024—likely due to a massive R&D acquisition or IP-related write-off—the underlying cash flow generation remains robust. The company maintains a fortress balance sheet with zero long-term debt and…
Top Opportunities
- Zero long-term debt for a decade
- Dominant monopoly in Cystic Fibrosis (CF) market
- Exceptional 10-year revenue CAGR (>40%)
Top Risks
- High concentration risk in Cystic Fibrosis franchise
- Net loss in 2024 due to high M&A costs
- Negative OCF in 2024
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.